PROM1 and neoplasm: Although previous work reported that CD133+-xenografted cells are more resistant than CD133− cells to gemcitabine treatment [8], we found that cells expressing CSC markers were not particularly more resistant to a standard treatment than the other cells within the tumor, as presented in Figure 4 and 5.